Data from Israel’s real-world experience with Pfizer/Biontech’s Covid-19 vaccine should silence any doubters.
New findings for IL-6 blockade in the Recovery trial finally confirm a signal. Can pending pandemic readouts for other mechanisms do the same?
Today’s safety scare with Lentiglobin calls into question the logic behind Bluebird’s planned business separation.
Amicus follows Sanofi with disappointing pivotal Pompe data, casting further doubt on approvals.
Will it be a new class of cancer drug or another failure for Novartis’s IL-1 inhibitor?
Toxicity worries send yet another Gilead/Galapagos project, ziritaxestat, to the scrapheap.